Syneron Medical (ELOS) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. INTC
2. DSX
3. GNK
4. TTEC
5. DAL
6. AWK
7. SPCX
8. III
9. DFTX
10. ABNAF

Go back to Syneron Medical (ELOS) Reports In-Line Q3 EPS

Syneron Medical Reports Third Quarter 2015 Revenue of $62.1 Million

November 11, 2015 7:00 AM EST

IRVINE, Calif., Nov. 11, 2015 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, today announced financial results for the three month period ended September 30, 2015.

Third Quarter 2015 and Recent Non-GAAP[1] Highlights:

Revenue of $62.1 million, compared to $60.3 million in the third quarter 2014, up 3% year-over-year, or 8% in constant currency North American product sales grew 15% year-over-year Non-GAAP gross margin of 57.0%, or 58.9% in constant currency, compared to 55.6% in Q3 2014 Non-GAAP net income of... More

Syneron Medical Appoints Jeff Nardoci as President of North America Body Shaping Group

November 11, 2015 6:59 AM EST

IRVINE, Calif., Nov. 11, 2015 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that it has enhanced its North American leadership team with the appointment of Jeff Nardoci as President of its North America Body Shaping Group. In this position, Mr. Nardoci will be responsible for the development and execution of the Company's growth strategies for UltraShape and VelaShape. He will report to Bill Griffing, CEO of Syneron Candela North America.

Amit Meridor, Chief... More